Experienced in Burkitt Lymphoma

Dr. Katarzyna J. Jamieson

Hematology Oncology | Hematology | Oncology
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Burkitt Lymphoma
University Of North Carolina At Chapel Hill
101 Manning Dr, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katarzyna Jamieson is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Jamieson is rated as an Experienced provider by MediFind in the treatment of Burkitt Lymphoma. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jamieson is currently accepting new patients.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Burkitt Lymphoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Biological, Drug
Study Drugs: ATLCAR.CD30 T cells, Bendamustine, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Suspended
Publish Date: September 22, 2025
Intervention Type: Biological
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
View 5 Less Clinical Trials

22 Total Publications

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2025
Similar Doctors
Sandeep S. Dave
Distinguished in Burkitt Lymphoma
Dr. Sandeep S. Dave
Hematology Oncology | Oncology
Distinguished in Burkitt Lymphoma
Dr. Sandeep S. Dave
Hematology Oncology | Oncology
2100 Erwin Rd, 
Durham, NC 
 (9.8 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandeep Dave is a Hematologist Oncology specialist and an Oncologist in Durham, North Carolina. Dr. Dave is rated as a Distinguished provider by MediFind in the treatment of Burkitt Lymphoma. His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Adenoidectomy. Dr. Dave is currently accepting new patients.

Advanced in Burkitt Lymphoma
Dr. Joellen C. Speca
Hematology Oncology | Hematology | Oncology
Advanced in Burkitt Lymphoma
Dr. Joellen C. Speca
Hematology Oncology | Hematology | Oncology

Rex Hospital Inc

4420 Lake Boone Trl, 
Raleigh, NC 
 (20.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joellen Speca is a Hematologist Oncology specialist and a Hematologist in Raleigh, North Carolina. Dr. Speca is rated as a Distinguished provider by MediFind in the treatment of Burkitt Lymphoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Smoldering Multiple Myeloma. Dr. Speca is currently accepting new patients.

Advanced in Burkitt Lymphoma
Dr. William A. Wood
Hematology Oncology | Hematology | Oncology
Advanced in Burkitt Lymphoma
Dr. William A. Wood
Hematology Oncology | Hematology | Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (0.1 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Wood is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Wood is rated as a Distinguished provider by MediFind in the treatment of Burkitt Lymphoma. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Wood is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamieson's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile